Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study

Trial Profile

Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Evacetrapib (Primary)
  • Indications Cardiovascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms ACCELERATE
  • Sponsors Eli Lilly
  • Most Recent Events

    • 30 Aug 2017 Results assessing the impact of lipid modification with evacetrapib on clinical outcomes in diabetes mellitus patients, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 30 Aug 2017 Results assessing the impact of Evacetrapib on the glycemic profile in statin treated patients in the ACCELERATE trial, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
    • 16 Nov 2016 Results of effect of evcetrapib on cholesterol efflux capacity presented at the 89th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top